AR025780A1 - Formulacion de antagonista de vasopresina y su proceso - Google Patents

Formulacion de antagonista de vasopresina y su proceso

Info

Publication number
AR025780A1
AR025780A1 ARP000105036A ARP000105036A AR025780A1 AR 025780 A1 AR025780 A1 AR 025780A1 AR P000105036 A ARP000105036 A AR P000105036A AR P000105036 A ARP000105036 A AR P000105036A AR 025780 A1 AR025780 A1 AR 025780A1
Authority
AR
Argentina
Prior art keywords
vasopresine
component
pharmaceutically acceptable
antagonist formulation
formulations
Prior art date
Application number
ARP000105036A
Other languages
English (en)
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of AR025780A1 publication Critical patent/AR025780A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta provee formulaciones de N-[4-(5H-pirrolo[2,1-c][1,4]benzodiazepin-10(11H)ilcarbonil)-3-clorofenil]-5-fluoro-2-metilbenzamida, o su salfarmacéuticamente aceptable, y a los procesos para prepararlas, las formulaciones comprenden entre alrededorde l 1% y alrededor del 20% del ingrediente activo,entre alrededor del 1% y alrededor del 18% de un componente surfactante, entre alrededor del 50% y alrededor del 80% de un componente de uno o más polietilénglicoles, entre alrededor del 1% yalrededor del 20% de un componente de uno o más ésteres de ácido graso de sacarosa y/o polivinilpirrolidona y,opcionalmente, uno o más conservantes o anti-oxidantes farmacéuticamente aceptables.
ARP000105036A 1999-09-27 2000-09-26 Formulacion de antagonista de vasopresina y su proceso AR025780A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40577299A 1999-09-27 1999-09-27

Publications (1)

Publication Number Publication Date
AR025780A1 true AR025780A1 (es) 2002-12-11

Family

ID=23605168

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105036A AR025780A1 (es) 1999-09-27 2000-09-26 Formulacion de antagonista de vasopresina y su proceso

Country Status (18)

Country Link
EP (1) EP1216033A1 (es)
JP (1) JP2003510269A (es)
KR (1) KR20020039354A (es)
CN (1) CN1391466A (es)
AR (1) AR025780A1 (es)
AU (1) AU7615000A (es)
BR (1) BR0014351A (es)
CA (1) CA2388474A1 (es)
CZ (1) CZ20021083A3 (es)
EA (1) EA200200414A1 (es)
HK (1) HK1045109A1 (es)
HU (1) HUP0202972A3 (es)
IL (1) IL148541A0 (es)
MX (1) MXPA02003189A (es)
NO (1) NO20021475L (es)
PL (1) PL354282A1 (es)
WO (1) WO2001022945A1 (es)
ZA (1) ZA200203312B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
AU2003211267A1 (en) * 2002-02-27 2003-09-09 Shionogi And Co., Ltd. Solid preparations with improved absorbability of hardly water-soluble drug
JP5873375B2 (ja) * 2012-04-03 2016-03-01 中日本カプセル 株式会社 ソフトカプセル及びソフトカプセルの製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516774A (en) * 1993-07-29 1996-05-14 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
CA2318128C (en) * 1998-01-20 2008-10-14 Applied Analytical Industries, Inc. Oral liquid compositions

Also Published As

Publication number Publication date
CZ20021083A3 (cs) 2002-06-12
KR20020039354A (ko) 2002-05-25
CN1391466A (zh) 2003-01-15
NO20021475D0 (no) 2002-03-25
AU7615000A (en) 2001-04-30
IL148541A0 (en) 2002-09-12
HUP0202972A3 (en) 2003-07-28
EA200200414A1 (ru) 2002-12-26
CA2388474A1 (en) 2001-04-05
NO20021475L (no) 2002-04-16
HK1045109A1 (zh) 2002-11-15
MXPA02003189A (es) 2002-09-30
WO2001022945A1 (en) 2001-04-05
JP2003510269A (ja) 2003-03-18
BR0014351A (pt) 2002-06-11
PL354282A1 (en) 2003-12-29
HUP0202972A2 (hu) 2002-12-28
ZA200203312B (en) 2003-12-31
EP1216033A1 (en) 2002-06-26

Similar Documents

Publication Publication Date Title
ECSP055528A (es) Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco
AR002355A1 (es) Composiciones y metodos para administracion local de agentes farmaceuticamente activos.
DK1021204T3 (da) Bioadhæsive præparater og fremgangsmåder til topisk administration af aktive midler
ES2178037T3 (es) Derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que los contienen.
CA2271196A1 (en) Pharmaceutical compositions of hiv protease inhibitors with improved oral bioavailability
BR9806157A (pt) Composições farmacêuticas de descarboetoxiloratadina anidras, não higroscópicas e sem lactose
WO2001007049A3 (en) Ophthalmic composition comprising ketotifen
ES2065846B1 (es) Formulacion farmaceutica a base de un agente antiinflamatorio esteroidico o no esteroidico y un antibiotico pertenciente al grupo de los inhibidores de la adn girasa para su utilizacion topica oftalmica.
AR025780A1 (es) Formulacion de antagonista de vasopresina y su proceso
ES2134237T3 (es) Composiciones farmaceuticas que contienen acido ursodesoxicolico.
WO2003082881A3 (en) Pyridoxal-5-phosphate derivatives as hiv integrase inhibitors
WO2001034129A3 (en) Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use
WO2001022969A3 (en) Vasopressin agonist formulation and process
ECSP941088A (es) Composiciones
YU6396A (sh) Kombinacija inhibitora hiv proteaze sa drugim jedinjenjima za terapiju hiv infekcija
NO20021476L (no) Farmasöytisk b¶rerformulering
FI932654A0 (fi) Hydroxamsyraderivat, som hindrar lipoxigenas
ATE286395T1 (de) Antithrombotische mittel
ES2121109T3 (es) Composicion de champu.
NZ521533A (en) Veterinary compositions for the treatment of parasitic diseases containing rafoxanide
RU2008115908A (ru) Фармацевтическая композиция, содержащая гиалуронидазу и липосомы для наружного применения
AR013758A1 (es) Terapia de combinacion para el tratamiento de sida.
IE780921L (en) 1-acyl-2-hydroxy-1,3-diamino-propanes.
AU1022401A (en) Cleaning agents which contain surfactants and enzyme inhibitors
UY27033A1 (es) Nuevos compuestos para su uso como inhibidores de la proteasa de vih